Skip to content

US · ETON · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Eton Pharmaceuticals, Inc. (ETON) intrinsic value and stock valuation

$60.85as of 2026-11-21 · Mkt cap 1.22B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eton Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ETON with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from ETON’s statements →

Eton Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Deer Park, IL 60010-7278 etonpharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$80M+357.2% 5y CAGRd
20172025
Net income
-$-4.6M
20172025
Free cash flow
$10.2M
20172025
Total equity
$26.2M+10.8% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$80M$39M$31.6M$21.3M$21.8M
Operating income$70K-$-2.6M-$-1.19M-$-8.26M-$-1.5M
Net income-$-4.6M-$-3.82M-$-940K-$-9.02M-$-1.96M
EPSd-$-170.94K-$-147.55K-$-36.65K-$-358.65K-$-77.75K
Operating cash flow$10.5M$970K$6.82M$4.82M-$-4.72M
Capital expenditure-$-330K-$-30K-$-780K-$-2.79M-$-3.26M
Free cash flow$10.2M$940K$6.04M$2.03M-$-7.98M
Total assets$92.1M$76.1M$31.7M$25M$27.5M
Total debt$31M$30M$5.4M$6.52M$6.7M
Net debt$5.08M$15.1M-$-15.99M-$-9.78M-$-7.71M
Total equity$26.2M$24.4M$15.5M$13.1M$17.6M
Cash and short-term investments$25.9M$14.9M$21.4M$16.3M$14.4M
Income statement
20252024202320222021
Revenue$80M$39M$31.6M$21.3M$21.8M
Cost of revenue$37.2M$15.6M$10.6M$6.93M$2.62M
Gross profit$42.7M$23.4M$21.1M$14.3M$19.2M
Research and development expenses$7.76M$3.25M$3.32M$4M$6.24M
Selling, general and administrative expenses$35.8M$22.8M$18.9M$18.6M$14.5M
Other expenses-$-920K$0.00$0.00$0.00$0.00
Operating expenses$42.7M$26M$22.3M$22.6M$20.7M
Cost and expenses$79.9M$41.6M$32.8M$29.5M$23.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$4.78M$2M$1.06M$950K$1.04M
Depreciation and amortization$4.04M$1.15M$900K$1.77M$460K
Ebitda$4.27M-$-660K$210K-$-7.25M-$-1.49M
Operating income$70K-$-2.6M-$-1.19M-$-8.26M-$-1.5M
Total other income/expenses, net-$-4.63M-$-1.21M$500K-$-760K-$-460K
Income before tax-$-4.56M-$-3.81M-$-690K-$-9.02M-$-1.96M
Income tax expense$40K$10K$250K$0.00$0.00
Net income-$-4.6M-$-3.82M-$-940K-$-9.02M-$-1.96M
Weighted average shares outstanding$26.9M$25.9M$25.6M$25.2M$25.2M
Weighted average diluted shares outstanding$26.9M$25.9M$25.7M$25.2M$25.2M
Balance sheet
20252024202320222021
Cash and short-term investments$25.9M$14.9M$21.4M$16.3M$14.4M
Net receivables$11.8M$5.36M$3.41M$1.85M$5.47M
Inventory$15.4M$15.2M$910K$560K$550K
Total current assets$60.6M$41M$26.8M$20M$23.6M
Property, plant and equipment, net$640K$210K$150K$260K$220K
Goodwill and intangible assets$30.9M$34.9M$4.74M$4.75M$3.62M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$31.5M$35.1M$4.9M$5.03M$3.86M
Total assets$92.1M$76.1M$31.7M$25M$27.5M
Accounts payable$11M$4.17M$1.85M$1.77M$1.77M
Short-term debt$8.79M$80K$5.38M$1.03M$1.42M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$38.5M$20M$16.2M$6.46M$4.56M
Long-term debt$22.2M$29.9M$20K$5.49M$5.28M
Deferred revenue, non-current$1.76M$0.00$0.00$0.00$0.00
Total non-current liabilities$27.5M$31.8M$20K$5.49M$5.28M
Capital lease obligations$460K$110K$20K$110K$10K
Total liabilities$66M$51.7M$16.3M$12M$9.84M
Common stock$30K$30K$30K$30K$30K
Retained earnings-$-112.49M-$-107.89M-$-104.07M-$-103.13M-$-94.11M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$26.2M$24.4M$15.5M$13.1M$17.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$31M$30M$5.4M$6.52M$6.7M
Net debt$5.08M$15.1M-$-15.99M-$-9.78M-$-7.71M
Cash flow statement
20252024202320222021
Net income-$-4.6M-$-3.82M-$-940K-$-9.02M-$-1.96M
Depreciation and amortization$4.04M$1.15M$900K$1.77M$460K
Stock-based compensation$5.51M$3.17M$3.14M$4.22M$3.38M
Change in working capital-$-860K-$-700K$3.53M$7.66M-$-6.21M
Accounts receivable-$-6.4M-$-3.12M-$-1.56M$3.62M-$-5.42M
Inventory-$-5.88M-$-1.31M-$-350K-$-10K$690K
Accounts payable$6.81M$2.32M$50K-$-10K-$-570K
Net cash provided by operating activities$10.5M$970K$6.82M$4.82M-$-4.72M
Investments in property, plant and equipment-$-330K-$-30K-$-780K-$-40K-$-3.26M
Acquisitions, net$0.00-$-30M$0.00$0.00$700K
Net cash used for investing activities-$-330K-$-40.01M-$-780K-$-2.79M-$-2.56M
Common stock issued$600K$8.19M$0.00$0.00$540K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$810K$32.6M-$-960K-$-130K$390K
Net change in cash$11M-$-6.45M$5.08M$1.9M-$-6.89M
Cash at end of period$25.9M$14.9M$21.4M$16.3M$14.4M
Operating cash flow$10.5M$970K$6.82M$4.82M-$-4.72M
Capital expenditure-$-330K-$-30K-$-780K-$-2.79M-$-3.26M
Free cash flow$10.2M$940K$6.04M$2.03M-$-7.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eton Pharmaceuticals, Inc.

        Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

        CEO
        Sean E. Brynjelsen
        Employees
        44
        Beta
        0.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Eton Pharmaceuticals, Inc. (ETON)?

        Eton Pharmaceuticals, Inc. (ETON) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ETON undervalued?

        ETON trades at a price of $60.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.